Evidence map›Paper›PMID 22661378›Full record

ReviewCurrent neurology and neuroscience reports2012

Botulinum toxin for the treatment of movement disorders.

Mary Ann Thenganatt, Stanley Fahn

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03508882 (Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03508882 phase4completednot on this mapstarted 2015, after this paper: background citation

Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm: a Randomized, Triple-blind, Placebo-controlled, Cross-over Clinical Trial

TypeinterventionalSponsorThe University of Hong KongRan2015 to 2019Enrolled100ConditionsBlepharospasm, Hemifacial Spasm, Botulinum Toxins, Type AArmsBotulinum Toxin Type A 100Unit/Vial (Product), Saline Solution for Injection
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Treatment of dystonia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014
    Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mary Ann ThenganattDepartment of Neurology, College of Physicians and Surgeons, Columbia University, 710 West 168th Street, New York, NY 10032, USA. mt2493@columbia.edu
Stanley Fahn
Columbia University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After botulinum toxin was initially used to treat strabismus in the 1970s, others started using it to treat movement disorders including blepharospasm, hemifacial spasm, cervical dystonia, spasmodic dysphonia, and oromandibular dystonia. It was discovered that botulinum toxin can be an effective treatment for focal movement disorders with limited side effects. Over the past three decades, various formulations of botulinum toxin have been developed and the therapeutic use of these toxins has expanded in movement disorders and beyond. We review the history and mechanism of action of botulinum toxin, as well as describe different formulations available and their potential therapeutic uses in movement disorders.

Indexed as

AnimalsBlepharospasmBotulinum ToxinsHemifacial SpasmHumansMovement DisordersTreatment OutcomeBotulinum Toxins

Identifiers

PMID22661378
OpenAlexW2072147078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.